Cite
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
MLA
Renato Fanin, et al. Dexamethasone plus Rituximab Yields Higher Sustained Response Rates than Dexamethasone Monotherapy in Adults with Primary Immune Thrombocytopenia. Jan. 2010. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....075770f87340e838aa95173f0f9da42d&authtype=sso&custid=ns315887.
APA
Renato Fanin, Rita Rizzi, Michele Baccarani, Patrizio Mazza, Emanuele Angelucci, Selenia Campagna, Silvia Cantoni, Enrica Gamba, Valerio De Stefano, Felicetto Ferrara, Giuseppe Visani, Marzia Defina, Franca Soldano, Sergio Amadori, Emilio Usala, Alfonso Zaccaria, Francesco Casulli, Alessia Tieghi, Antonella Fornaro, … Nicola Vianelli. (2010). Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
Chicago
Renato Fanin, Rita Rizzi, Michele Baccarani, Patrizio Mazza, Emanuele Angelucci, Selenia Campagna, Silvia Cantoni, et al. 2010. “Dexamethasone plus Rituximab Yields Higher Sustained Response Rates than Dexamethasone Monotherapy in Adults with Primary Immune Thrombocytopenia,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....075770f87340e838aa95173f0f9da42d&authtype=sso&custid=ns315887.